- Home
- SGN vs PRFX Comparison
SGN vs PRFX Comparison
Compare SGN & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGN | PRFX |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.7M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SGN | PRFX |
|---|---|---|
| Price | $0.25 | $2.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 77.4M | 1.3M |
| Earning Date | 11-12-2025 | 10-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $366,344.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $2.57 |
| 52 Week High | $4.27 | $27.35 |
Technical Indicators
Market Signals| Indicator | SGN | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 41.00 | 76.82 |
| Support Level | $0.17 | $2.57 |
| Resistance Level | $0.34 | $3.71 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | 0.04 | 0.24 |
| Stochastic Oscillator | 44.89 | 72.51 |
Price Performance
Historical ComparisonAbout SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.